Skip to main content

Table 4 Cost-utility and cost-effectiveness analysis (discounted data)

From: Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model

a. Cost-utility
  Totala Incremental ICURb Incremental ICURb
(vs. previous alternative) (vs. previous alternative) (vs. no vaccination) (vs. no vaccination)
  QALYs Costs QALYs Costs QALYs Costs
Current screening practice 2126963 14272773 - - - - -
HPV-6/11/16/18 vaccine + current screening 2127782 14715753 819 442981 Dominated 819 442981 541
HPV-16/18 + current screening 2127811 14371468 29 -344286 116 848 98695 116
b. Cost-effectiveness
  Total a Incremental ICER b Incremental ICER b
(vs. previous alternative) (vs. previous alternative) (vs. no vaccination) (vs. no vaccination)
  LYS Costs LYS Costs QALYs Costs
Current screening practice 2127239 14272773 - - - - -
HPV-6/11/16/18 vaccine + current screening 2127849 14715753 610 442981 Dominated 610 442981 726
HPV-16/18 + current screening 2127909 14371468 60 - 344286 147 670 98695 147
  1. aStrategies are listed in order of increasing health gains (QALYs). bICUR & ICER calculations for both vaccines are obtained by comparing to previous alternative and to the reference (no vaccination) scenario. Costs and health outcomes were discounted at an annual rate of 6.0% based on the recommendations of the Planning Ministry of Chile [42].
  2. Note: HPV: human papillomavirus; ICUR: incremental cost-utility ratio; ICER: incremental cost-effectiveness ratio; LYS: Life-years saved; QALY: quality-adjusted life years.
\